Therapy Areas: Central Nervous System
Solvonis signs Portugal agreement to assess European expansion of Phase 3 alcohol addiction trial
13 October 2026 - Solvonis Therapeutics plc (LON:SVNS), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for central nervous system (CNS) disorders, said on Tuesd...
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
30 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its N...
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
16 September 2026 - Skyhawk Therapeutics Inc, a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announced on Tuesday the final 15-month...
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
28 August 2026 - Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company based in Sydney, Australia, announced on Thursday new data showing that its lead asset, paxalisi...
Leal Therapeutics announces USD30m Series A extension and initiates Phase 1b/2a clinical trial of LTX-001 in schizophrenia
18 August 2026 - Leal Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics, announced on Monday a second close of USD30m of its Series A fina...
Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment
12 August 2026 - Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabol...